Results 41 to 50 of about 383,013 (128)
UEG Week 2024 Moderated Posters
United European Gastroenterology Journal, Volume 12, Issue S8, Page 201-664, October 2024.
wiley +1 more source
Analysis of published and unpublished sitagliptin (Januvia) studies in humans
, 2014 August 25, 2014 5 pm Bogotá time zone Sitagliptin (Januvia) ClinicalTrials.gov records completed before Jan 2011. Total number of records = 115Expert search terms (PubMed): http://goo.gl/pIdDaQ Records not found = 85Results = 40 Expert search terms of ...
Jorge H Ramirez (587826)
core +1 more source
Laser damage threshold studies in L-arginine phosphate monohydrate
, 1994 The semiorganic L-arginine phosphate monohydrate crystals were grown from aqueous solutions by slow cooling. Single shot damage threshold of LAP was measured and compared with other nonlinear materials.
Subramanian, CK +4 more
core +1 more source
, 2017 A new simple, rapid, specific, accurate, precise and novel Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method has been developed for the estimation of Sitagliptin Phosphate in the pharmaceutical dosage form.
Vasudha Bakshi +3 more
core +1 more source
In 2007, sitagliptin, the first drug in a new family of oral glucose-lowering drugs, was introduced to the UK market. When hyperglycemia is present, it suppresses the secretion of glucagon and increases the secretion of insulin. The goal of the current study is to use lactose as a diluent in a direct compression approach to create a novel drug delivery
openaire +1 more source
ABSTRACT:For measuring EMPA and SPM in bulk and pharmaceutical forms to created a accurate and affordable UVspectrophotometric method. Both tested medications in a water and methanol mix (70:30). EMPA absorbs light at 224nm and SPM at 267 nm, which we found by scanning light wavelengths from 200 to 400nm.
openaire +1 more source
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
, 2010 Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1).
Ahren B, Bo Ahrén
core
According to WHO,diabetes as a long-term metabolic disease characterized by elevated blood glucose levels. This could cause minor harm to the heart, kidneys, nerves, blood vessels, and eye. This review provides detail information to help researchers and analysts to select appropriate methods of analysis, quantitative by providing an idea of different ...
Sellappan Malathi +2 more
openaire +1 more source
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
, 2009 Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval ...
Jonathan K Reynolds
core
, 2007 AIM: To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin ...
Fanurik, D +6 more
core +1 more source